Abstract

Mast cells are implicated as detrimental players in inflammatory lung diseases, particularly asthma. Mast cells respond to activating stimuli by releasing a wide panel of pro-inflammatory compounds that can contribute profoundly to the pathology, and there is currently an unmet need for strategies that efficiently ameliorate harmful effects of mast cells under such conditions. Here, we sought to evaluate a novel concept for targeting human lung mast cells, by assessing the possibility of selectively depleting the lung mast cells by induction of apoptosis. For this purpose, we used lysosomotropic agents, i.e., compounds that are known to permeabilize the secretory granules of mast cells, thereby releasing the contents of the granules into the cytosol. Either intact human lung tissue, purified human lung mast cells or mixed populations of human lung cells were incubated with the lysosomotropic agents mefloquine or siramesine, followed by measurement of apoptosis, reactive oxygen species (ROS) production, and release of cytokines. We show that human lung mast cells were highly susceptible to apoptosis induced by this strategy, whereas other cell populations of the lung were largely refractory. Moreover, we demonstrate that apoptosis induced by this mode is dependent on the production of ROS and that the treatment of lung tissue with lysosomotropic agents causes a decrease in the release of pathogenic cytokines. We conclude that selective apoptosis of human lung mast cells can be accomplished by administration of lysosomotropic agents, thus introducing the possibility of using such drugs as novel therapeutics in the treatment of inflammatory lung disorders such as asthma.

Highlights

  • Mast cells are innate immune cells, which reside in tissues that are exposed to the external environment, such as skin, intestine, and lung

  • To assess the effect of lysosomotropic agents, mefloquine and siramesine, on human lung mast cells, specimens were obtained from the non-tumor parts of lung tissue dissected during lung cancer surgery

  • We showed that treatment of murine cultured mast cells (BMMCs) with a lysosomotropic agent caused the production of reactive oxygen species (ROS) and that the production of ROS had a central role in the induction of cell death [12]

Read more

Summary

Introduction

Mast cells are innate immune cells, which reside in tissues that are exposed to the external environment, such as skin, intestine, and lung. They leave bone marrow as immature myeloid cells, migrate through blood to peripheral tissues where they mature [1]. Mast cells are rich in lysosome-like organelles, denoted granules, that are filled with potent preformed compounds, such as histamine, serotonin, serglycin proteoglycans, certain preformed cytokines (e.g., TNF), growth factors (e.g., VEGF), Abbreviations: NAC, N-acetylcysteine; BMMC, bone marrow-derived mast cells; ROS, reactive oxygen species. Activated mast cells produce several other compounds de novo, such as prostaglandins and leukotrienes, cytokines, and chemokines [3]. The combined actions of all of these released compounds can cause a massive inflammatory reaction, with anaphylactic shock being a serious manifestation

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call